Department of Cardiology, Howard University Hospital, Washington, DC, United States of America.
Department of Internal Medicine, Howard University Hospital, Washington, DC, United States of America.
Cardiovasc Revasc Med. 2020 Nov;21(11):1398-1404. doi: 10.1016/j.carrev.2019.10.004. Epub 2019 Oct 18.
Percutaneous coronary intervention (PCI) is the standard procedure of care for most patients with non-ST elevation acute coronary syndrome (NSTE-ACS). However, the timing of PCI remains unclear. We performed this meta-analysis with available randomized controlled trials (RCTs) to compare early versus late coronary intervention in patients with NSTE-ACS.
A total of 13 RCTs were selected through PubMed/MEDLINE via OVID, EMBASE via OVID and Cochrane Central Register of Controlled Trials (inception to October 2018) search. Outcomes were analyzed using the relative risk (RR) and 95% CI. Pooled RRs were determined using M-H random-effects model, which can account for between study heterogeneity.
We included 13 RCTs with 11,972 patients were included. There were 7101 patients were randomized into early invasive group and 4871 in late invasive group. There was a significant decrease in myocardial infarction with long-term follow up in early invasive group compared to the delayed invasive group (RR 0.847 [95% CI 0.74-0.95], p = 0.009) with no difference in mortality between early and late invasive group (5.41% vs 6.49%, RR 0.882 [95% CI, 0.76-1.02]). On subgroup analysis, data was available from 6 RCTs for GRACE (Global Registry of Acute Coronary Events) score and 8 RCTs for elevated troponin. Early intervention led to decrease in adverse events in patients with elevated GRACE score > 140 (Mantel-Haenszel pooled RR 0.88 [95% CI 0.82-0.95], p-value 0.002) but no difference was seen in patients with elevated troponin.
It can be postulated from these results that early invasive strategy leads to decrease in myocardial infarction but without significant decrease in mortality. In patients with elevated GRACE score (>140), early intervention did show a trend towards decrease in major adverse cardiac events, whereas in patients with elevated troponin alone, similar association was not observed. However, adequately powered randomized controlled trial is necessary to validate these findings.
经皮冠状动脉介入治疗(PCI)是大多数非 ST 段抬高型急性冠状动脉综合征(NSTE-ACS)患者的标准治疗方法。然而,PCI 的时机仍不清楚。我们进行了这项荟萃分析,以比较 NSTE-ACS 患者的早期与晚期冠状动脉介入治疗。
通过 OVID 中的 PubMed/MEDLINE、OVID 中的 EMBASE 和 Cochrane 对照试验中心注册库(从 2018 年 10 月开始)检索,共纳入了 13 项随机对照试验(RCTs)。使用相对风险(RR)和 95%置信区间(CI)分析结果。使用 M-H 随机效应模型计算汇总 RR,可以考虑研究之间的异质性。
我们纳入了 13 项 RCTs,共纳入 11972 例患者。其中 7101 例患者被随机分配到早期介入组,4871 例患者被随机分配到晚期介入组。长期随访显示,早期介入组心肌梗死发生率显著降低(RR 0.847[95%CI 0.74-0.95],p=0.009),早期和晚期介入组死亡率无差异(5.41% vs 6.49%,RR 0.882[95%CI,0.76-1.02])。亚组分析中,有 6 项 RCT 提供了 GRACE(全球急性冠状动脉事件注册)评分的数据,8 项 RCT 提供了高肌钙蛋白的数据。早期干预可降低 GRACE 评分>140 的患者的不良事件发生率(Mantel-Haenszel 汇总 RR 0.88[95%CI 0.82-0.95],p 值=0.002),但在高肌钙蛋白患者中未见差异。
从这些结果可以推测,早期介入策略可降低心肌梗死发生率,但死亡率无显著降低。在 GRACE 评分升高(>140)的患者中,早期干预确实显示出减少主要不良心脏事件的趋势,而在单纯高肌钙蛋白的患者中,未见类似的相关性。然而,需要进行充分的随机对照试验来验证这些发现。